NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

INBX

Inhibrx Biosciences Inc

May 23 • 04:00PM ET

12.86

Dollar change +0.32
Percentage change 2.55	%

Healthcare • Biotechnology • USA • NASD

Peers: BPMC ARVN ONC PTCT EXEL PBYI ADAP KPTI IGMS

| Held by: VTI IWM VXF IWO IBB VTWO IWN FESM IWC EES

Scroll to Statements

Index	RUT	P/E	0.11	EPS (ttm)	119.22	Insider Own	31.84%	Shs Outstand	14.48M	Perf Week	4.30%
Market Cap	186.16M	Forward P/E	-	EPS next Y	-9.24	Insider Trans	0.00%	Shs Float	9.87M	Perf Month	7.35%
Income	1.72B	PEG	-	EPS next Q	-2.76	Inst Own	62.56%	Short Float	7.40%	Perf Quarter	2.96%
Sales	0.20M	P/S	930.81	EPS this Y	-109.95%	Inst Trans	10.19%	Short Ratio	6.36	Perf Half Y	-10.01%
Book/sh	6.52	P/B	1.97	EPS next Y	17.54%	ROA	648.69%	Short Interest	0.73M	Perf Year	-
Cash/sh	14.96	P/C	0.86	EPS next 5Y	-	ROE	3250.55%	52W Range	10.80 - 18.95	Perf YTD	-16.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	865.81%	52W High	-32.14%	Beta	-0.67
Dividend TTM	-	Quick Ratio	5.12	Sales past 5Y	-53.39%	Gross Margin	-1199.50%	52W Low	19.07%	ATR (14)	0.82
Dividend Ex-Date	-	Current Ratio	5.12	EPS Y/Y TTM	-	Oper. Margin	-150262.00%	RSI (14)	55.85	Volatility	4.08% 4.64%
Employees	161	Debt/Eq	1.13	Sales Y/Y TTM	-	Profit Margin	861485.50%	Recom	3.00	Target Price	12.00
Option/Short	Yes / Yes	LT Debt/Eq	1.11	EPS Q/Q	48.50%	Payout	0.00%	Rel Volume	0.64	Prev Close	12.54
Sales Surprise	-	EPS Surprise	1.23%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	114.76K	Price	12.86
SMA20	6.52%	SMA50	1.80%	SMA200	-8.08%	Trades		Volume	73,671	Change	2.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	JMP Securities	Mkt Perform

May-14-25 04:05PM	Inhibrx Reports First Quarter 2025 Financial Results (PR Newswire) +10.89%
Apr-01-25 04:05PM	Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President (PR Newswire)
Mar-17-25 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results (PR Newswire)
Jan-21-25 05:01PM	Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer (PR Newswire) +5.19%
Jan-13-25 04:15PM	Inhibrx Biosciences Announces Loan Agreement with Oxford Finance (PR Newswire) -6.60%
04:24PM	Loading…
Nov-14-24 04:24PM	Inhibrx Biosciences Reports Third Quarter 2024 Financial Results (PR Newswire) -7.25%
Nov-04-24 04:00PM	Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation (PR Newswire)
Sep-13-24 01:55AM	Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) (GuruFocus.com) +8.82%
Aug-13-24 06:54PM	Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (PR Newswire)
May-24-24 04:00PM	Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi (PR Newswire)
May-10-24 06:36PM	Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off (PR Newswire)

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kayyem Jon Faiz	Director	Nov 19 '24	Buy	14.23	69,686	991,416	51,093	Nov 22 04:03 PM
Kayyem Jon Faiz	Director	Nov 20 '24	Buy	14.19	37,500	532,204	69,843	Nov 22 04:03 PM
Lappe Mark	Chief Executive Officer	Sep 12 '24	Buy	15.05	26,963	405,793	692,511	Sep 16 05:12 PM
Lappe Mark	Chief Executive Officer	Sep 16 '24	Buy	17.13	13,037	223,324	705,548	Sep 16 05:12 PM
Vuori Kristiina MD	Director	Sep 11 '24	Buy	15.07	6,457	97,307	13,776	Sep 12 05:14 PM
Vuori Kristiina MD	Director	Sep 10 '24	Buy	15.00	179	2,685	7,319	Sep 12 05:14 PM
Lappe Mark	Chief Executive Officer	Sep 06 '24	Buy	15.29	26,000	397,540	647,548	Sep 10 05:00 PM
Lappe Mark	Chief Executive Officer	Sep 09 '24	Buy	15.21	9,500	144,495	657,048	Sep 10 05:00 PM
Lappe Mark	Chief Executive Officer	Sep 10 '24	Buy	15.19	8,500	129,115	665,548	Sep 10 05:00 PM
Lappe Mark	Chief Executive Officer	Sep 03 '24	Buy	15.81	20,000	316,263	165,000	Sep 03 05:31 PM
Lappe Mark	Chief Executive Officer	Aug 29 '24	Buy	14.03	10,000	140,300	135,000	Sep 03 05:31 PM
Lappe Mark	Chief Executive Officer	Aug 30 '24	Buy	14.02	10,000	140,200	145,000	Sep 03 05:31 PM
Vuori Kristiina MD	Director	Aug 29 '24	Buy	14.00	7,140	99,960	7,140	Sep 03 04:27 PM
MANHARD KIMBERLY	Director	Aug 28 '24	Buy	13.98	10,000	139,800	10,000	Aug 30 04:16 PM
FORSYTH DOUGLAS	Director	Aug 23 '24	Buy	14.07	59,812	841,555	224,564	Aug 26 04:26 PM
FORSYTH DOUGLAS	Director	Aug 22 '24	Buy	12.89	15,188	195,773	164,752	Aug 26 04:26 PM
Lappe Mark	Chief Executive Officer	Aug 20 '24	Buy	12.97	27,055	350,903	41,920	Aug 22 04:29 PM
Lappe Mark	Chief Executive Officer	Aug 21 '24	Buy	12.93	12,945	167,379	54,865	Aug 22 04:29 PM
Kayyem Jon Faiz	Director	Jun 05 '24	Buy	17.32	57,549	997,024	1,150,410	Jun 07 06:05 PM
Eckelman Brendan P.	Chief Scientific Officer	May 28 '24	Sale	34.30	300,000	10,290,000	1,735,553	May 30 06:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INBX

Inhibrx Biosciences Inc

Upgrade your FINVIZ experience